ReViral Overview

  • Founded
  • 2011
Founded
  • Status
  • Private
  • Employees
  • 25
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $45.6M
Latest Deal Amount
  • Investors
  • 10

ReViral General Information

Description

Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-class compounds. The company's antiviral drugs is a fusion inhibitor of RSV which is a highly potent, novel small molecule and is being developed to treat RSV in patients with severe disease including neonates, enabling patients to be treated who are infected with the respiratory syncopal virus (RSV) by developing novel compounds.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • Stevenage Bioscience Catalyst
  • Gunnels Wood Road, Hertfordshire
  • Stevenage SG1 2FX
  • England, United Kingdom

ReViral Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

ReViral Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 25-Aug-2020 $45.6M 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series B) 01-Aug-2018 000.00 000.00 00000 Completed Generating Revenue
3. Early Stage VC (Series A) 08-Sep-2015 000.00 000.00 000.00 Completed Generating Revenue
2. Angel (individual) 03-Dec-2014 $1.57M $1.83M Completed Generating Revenue
1. Angel (individual) 26-Feb-2013 $252K $252K 00000 Completed Startup
To view ReViral’s complete valuation and funding history, request access »

ReViral Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 00,000 00.000000 00000.00 00000.00 00 00000.00 00.000
Series B 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series A 00,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Series A 0,000 00.000000 0000.0 0000.0 00 0000.0 0.000
Ordinary 4,355 $0.013069 $6.53 $6.53 $6.53 2.17%
Ordinary 12,400 $0.013069
To view ReViral’s complete cap table history, request access »

ReViral Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of antiviral drugs designed to help patients and enlarge the antiviral market by developing novel first-in-cla
Drug Discovery
Stevenage, United Kingdom
25 As of 2021
00000
0000 0000-00-00
00000000000 00000

00000000

t dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut al
0000 000000000
Brighton, United Kingdom
00 As of 0000
000.00
00.00 0000-00-00
00000000000 000.00

00000000

ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in v
0000 000000000
Tucson, AZ
0 As of 0000
0000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ReViral Competitors (18)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enterprise Therapeutics Venture Capital-Backed Brighton, United Kingdom 00 000.00 00000000000 000.00
00000000 000000000 Corporation Tucson, AZ 0 0000000000
0000000 Venture Capital-Backed Singapore, Singapore 00 00000 00000 00000
000000 000000 Accelerator/Incubator Backed Morristown, NJ 0 00.000 0000000000 00.000
000000 00000000000 Formerly VC-backed Munich, Germany 000.00 000000&0 000.00
You’re viewing 5 of 18 competitors. Get the full list »

ReViral Patents

ReViral Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2021508341-A Pharmaceutical compound Pending 22-Dec-2017 00000000000
EP-3728220-A1 Pharmaceutical compounds Pending 22-Dec-2017 00000000000
GB-201721812-D0 Pharmaceutical compounds Ceased 22-Dec-2017 00000000000
US-11141406-B2 Pharmaceutical compounds Active 22-Dec-2017 00000000000 00
US-20200316030-A1 Pharmaceutical compounds Granted 22-Dec-2017 C07D403/06
To view ReViral’s complete patent history, request access »

ReViral Executive Team (10)

Name Title Board Seat Contact Info
Edward Littler Ph.D Chief Operating Officer
Stuart Cockerill Ph.D Chief Scientific Officer & Co-Founder
Neil Mathews Ph.D Co-Founder & Project Director
Rachel Harland Ph.D Head of Preclinical Development
Alex Sapir Chief Executive Officer & Board Member
You’re viewing 5 of 10 executive team members. Get the full list »

ReViral Board Members (14)

Name Representing Role Since
Alex Sapir Self Chief Executive Officer & Board Member 000 0000
Chau Khuong OrbiMed Board Member 000 0000
Iain Dukes Ph.D Self Board Member 000 0000
Isaac Manke Ph.D New Leaf Venture Board Member 000 0000
Jason Zhou China Resources Capital Management Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

ReViral Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ReViral Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Charoen Pokphand Group Corporation Minority 000 0000 000000 0
China Resources Capital Management Corporate Venture Capital Minority 000 0000 000000 0
Green Sands Equity Venture Capital Minority 000 0000 000000 0
Novo Holdings Venture Capital Minority 000 0000 000000 0
Perceptive Advisors Hedge Fund Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »